Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 5, 2005 - Issue 2
Submit an article Journal homepage
34
Views
4
CrossRef citations to date
0
Altmetric
Drug Profile

Clodronate in the prevention and treatment of skeletal metastasis

James Gulley National Cancer Institute, Director, Clinical Immunotherapy Group, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, 10 Center Drive, 8B07 MSC 1750, Bethesda, MD 20892, USA. [email protected]
&
William L Dahut National Cancer Institute, Chief Genitourinary Clinical Research Section, Medical Oncology Clinical Research Unit, Center for Cancer Research, 10 Center Drive, 12N226, Bethesda, MD 20892, USA. [email protected]
Pages 221-230 | Published online: 10 Jan 2014

References

  • Pfeilschifter J, Mundy GR. Modulation of type-β transforming growth-factor activity in bone cultures by osteotropic hormones. Proc. Natl Acad. Sci. USA 84(7), 2024–2028 (1987).
  • Mundy GR. Mechanisms of bone metastasis. Cancer 80(8 Suppl.), 1546–1556 (1997).
  • Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5´-(β, γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J. Bone Miner. Res. 12(9), 1358–1367 (1997).
  • Taube T, Elomaa I, Blomqvist C, Beneton MNC, Kanis JA. Comparative effects of clodronate and calcitonin on bone in metastatic breast cancer – a histomorphometric study. Eur. J. Cancer 29A(12), 1677–1681 (1993).
  • Plosker GL, Goa KL. Clodronate – a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 47(6), 945–982 (1994).
  • Peck WA. Results of a randomized study of clodronate in treating cancer-related hypercalcemia. Arch. Intern. Med. 147(11), 2056 (1987).
  • Delmas PD, Chapuy MC, Vignon E et al. Long-term effects of dichloromethylene diphosphonate in Paget’s disease of bone. J. Clin. Endocrinol. Metab. 54(4), 837–844 (1982).
  • Witte RS, Koeller J, Davis TE et al. Clodronate – a randomized study in the treatment of cancer-related hypercalcemia. Arch. Intern. Med. 147(5), 937–939 (1987).
  • Borgstrom GH, Elomaa I, Blomqvist C, Porkka L. Cytogenetic investigations of patients on clodronate therapy for Pagets disease of bone. Bone 8, S85–S86 (1987).
  • Gray RE, Yates AJ, Preston CJ, Smith R, Russell RG, Kanis JA. Duration of effect of oral diphosphonate therapy in Paget’s disease of bone. QJ Med. 64(245), 755–767 (1987).
  • Elomaa I, Blomqvist C, Porkka L et al. Clodronate for osteolytic metastases due to breast cancer. Biomed. Pharmacother. 42(2), 111–116 (1988).
  • Yakatan GJ, Poynor WJ, Talbert RL et al. Clodronate kinetics and bioavailability. Clin. Pharmacol. Ther. 31(3), 402–410 (1982).
  • Conrad KA, Lee SM. Clodronate kinetics and dynamics. Clin. Pharmacol. Ther. 30(1), 114–120 (1981).
  • Lapham G, Aranko K, Hanhijarvi H, Humphreys DM. Bioavailability of two clodronate formulations. Br. J. Hosp. Med. 56(5), 231–233 (1996).
  • Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J. Intern. Med. 246(1), 67–74 (1999).
  • Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol. 11(1), 59–65 (1993).
  • Elomaa I, Blomqvist C, Porkka L, Lambergallardt C, Borgstrom GH. Treatment of skeletal disease in breast cancer – a controlled clodronate trial. Bone 8, S53–S56 (1987).
  • Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst. Rev. (1), CD003474 (2002).
  • Kanis JA, Powles T, Paterson AHG, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19(6), 663–667 (1996).
  • Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br. J. Cancer 55(1), 61–66 (1987).
  • Diel IJ, Solomayer EF, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 339(6), 357–363 (1998).
  • Jaschke A, Bastert G, Solonmayer EF, Costa S, Schuetz F, Diel IJ. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow – a longtime follow-up. J. Clin. Oncol. 22(14S) (2004) (Abstract 529).
  • Powles T, Paterson S, Kanis JA et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J. Clin. Oncol. 20(15), 3219–3224 (2002).
  • Powles T, McCloskey E, Kurkilahti M. Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial. J. Clin. Oncol. 22(14S) (2004) (Abstract 528).
  • Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J. Clin. Oncol. 19(1), 10–17 (2001).
  • Saarto T, Vehmanen L, Blomqvist C, Elomaa I. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. J. Clin. Oncol. 22(14S) (2004) (Abstract 527).
  • Dearnaley DP, Sydes MR, Mason MD et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 trial). J. Natl Cancer Inst. 95(17), 1300–1311 (2003).
  • Mason MD, MRC PR04 Collaborators. Development of bone metastases from prostate cancer: first results of the MRC PR04 trial (ISCRTN 61384873). J. Clin. Oncol. 22(14S) (2004) (Abstract 4511).
  • Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J. Urol. 165(1), 136–140 (2001).
  • Kylmala T, Tammela T, Risteli L, Risteli J, Taube T, Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with Type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur. J. Cancer 6, 821–825 (1993).
  • Ernst DS, Brasher P, Hagen N, Paterson AH, MacDonald RN, Bruera E. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J. Pain Symptom Manage. 13(6), 319–326 (1997).
  • Vorreuther R. Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma – a pilot study on clodronate. Br. J. Urol. 72(5), 792–795 (1993).
  • Kylmala T, Tammela TLJ, Lindholm TS, Seppanen J. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann. Chir. Gynaecol. 83(4), 316–319 (1994).
  • Adami S, Mian M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res. 116, 67–72 (1989).
  • Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94(19), 1458–1468 (2002).
  • Luzzani M, Vidili MG, Rissotto R et al. Disodium clodronate in the treatment of pain due to bone metastases. Int. J. Clin. Pharmacol. Res. 10(4), 243–246 (1990).
  • Piga A, Bracci R, Ferretti B et al. A double-blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy. J. Exp. Clin. Cancer Res. 17(2), 213–217 (1998).
  • Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain – a double-blind, placebo-controlled study. J. Clin. Oncol. 13(9), 2427–2430 (1995).
  • Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J. Clin. Oncol. 22(13), 2546–2553 (2004).
  • Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J. Urol. 161(4), 1219–1222 (1999).
  • Powles TJ, McCloskey E, Paterson AHG et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J. Natl Cancer Inst. 90(9), 704–708 (1998).
  • Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J. Clin. Oncol. 15(4), 1341–1347 (1997).
  • Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with adjuvant anti-oestrogens. Br. J. Cancer 75(4), 602–605 (1997).
  • Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J. Urol. 169(6), 2008–2012 (2003).
  • Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 345(13), 948–955 (2001).
  • Vehmanen L, Saarto T, Elomaa I, Makela P, Valimaki M, Blomqvist C. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur. J. Cancer 37(18), 2373–2378 (2001).
  • Brown JE, McCloskey E, Dewar JA et al. A double-blind, parallel, placebo-controlled, dose ranging study on efficacy and safety of oral clodronate in cancer induced osteolysis measured by biochemical markers of bone resorption. J. Clin. Oncol. 22(14S) (2004) (Abstract 8056).
  • Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. 21(21), 4042–4057 (2003).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.